Abstract
Aim: We aimed to explore the role of urotensin 2 (UTS2) in glioblastoma (GBM).
Background: GBM is the most malignant primary brain cancer with a poor prognosis. Previous studies have suggested that GBM vessels undergo dynamic remodeling modulated by tumor vasodilation and vasoconstriction instead of tumor angiogenesis.
Objective: Here, we have first investigated the expression and function of UTS2, a potent vasoconstrictor, in GBM.
Methods: The mRNA expression profiles and clinical information of GBM patients were obtained from the TCGA database. The clinical relevance of UTS2 was explored by the Mann-Whitney U test and Cox hazard regression survival test. We further explored the role of UTS2 in GBM cell proliferation, migration, and tumor immune microenvironment. Moreover, we established the in vivo mice model to validate its oncogenic effects on GBM progression.
Results: Although we did not find significant correlations between UTS2 expression and patients’ clinical characteristics, UTS2 was identified as a valid independent prognostic indicator according to multivariate survival analysis. Knockdown of UTS2 resulted in decreased GBM cell proliferation and migration. In addition, functional enrichment analysis implied UTS2 to be involved in the regulation of the immune microenvironment. In vivo studies showed that UTS2 knockdown suppressed GBM xenograft growth, highlighting the tumor-promoting effects of UTS2 on GBM.
Conclusion: Our study identified that UTS2 could predict the prognosis of GBM patients and provided evidence regarding its oncogenic effects both in vitro and in vivo.
Keywords: Glioblastoma multiform, vasoconstriction, cell proliferation, survival analysis, immune activation, potent vasoconstrictor.
Current Cancer Drug Targets
Title:Prognostic Significance and Functional Mechanism of UTS2 in Glioblastoma Multiforme
Volume: 25 Issue: 6
Author(s): Yanfei Wang, Langping Shen and Mingzhong Sun*
Affiliation:
- Laboratory Department, Yancheng Third People’s Hospital, Yancheng 224008, China
Keywords: Glioblastoma multiform, vasoconstriction, cell proliferation, survival analysis, immune activation, potent vasoconstrictor.
Abstract:
Aim: We aimed to explore the role of urotensin 2 (UTS2) in glioblastoma (GBM).
Background: GBM is the most malignant primary brain cancer with a poor prognosis. Previous studies have suggested that GBM vessels undergo dynamic remodeling modulated by tumor vasodilation and vasoconstriction instead of tumor angiogenesis.
Objective: Here, we have first investigated the expression and function of UTS2, a potent vasoconstrictor, in GBM.
Methods: The mRNA expression profiles and clinical information of GBM patients were obtained from the TCGA database. The clinical relevance of UTS2 was explored by the Mann-Whitney U test and Cox hazard regression survival test. We further explored the role of UTS2 in GBM cell proliferation, migration, and tumor immune microenvironment. Moreover, we established the in vivo mice model to validate its oncogenic effects on GBM progression.
Results: Although we did not find significant correlations between UTS2 expression and patients’ clinical characteristics, UTS2 was identified as a valid independent prognostic indicator according to multivariate survival analysis. Knockdown of UTS2 resulted in decreased GBM cell proliferation and migration. In addition, functional enrichment analysis implied UTS2 to be involved in the regulation of the immune microenvironment. In vivo studies showed that UTS2 knockdown suppressed GBM xenograft growth, highlighting the tumor-promoting effects of UTS2 on GBM.
Conclusion: Our study identified that UTS2 could predict the prognosis of GBM patients and provided evidence regarding its oncogenic effects both in vitro and in vivo.
Export Options
About this article
Cite this article as:
Wang Yanfei, Shen Langping and Sun Mingzhong*, Prognostic Significance and Functional Mechanism of UTS2 in Glioblastoma Multiforme, Current Cancer Drug Targets 2025; 25 (6) . https://dx.doi.org/10.2174/0115680096275291231226081320
DOI https://dx.doi.org/10.2174/0115680096275291231226081320 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Magnetic Resonance Imaging in Myocardial Iron Assessment
Current Cardiology Reviews NOS Inhibitors: Structure, Biological Activity and Mechanism of Action
Current Enzyme Inhibition Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Fatal Lactic Acidosis Precipitated by Nifedipine in a Patient Treated with Disulfiram and Antiretrovirals
Drug Metabolism Letters From Discovery to Clinical Trials: Treatment Strategies for Central Neuropathic Pain after Spinal Cord Injury
Current Pharmaceutical Design Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Predictors of Conversion to Dementia of Probable Alzheimer Type in Patients with Mild Cognitive Impairment
Current Alzheimer Research Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research Long-Term Survivors of Cancer in Childhood and Adolescence
Current Pediatric Reviews Forceps: Still an Option?
Current Women`s Health Reviews PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets